As we dig deeper into the issue of prescription drug safety and the multitude of issues surrounding the manufacture, distribution and profit from pharmaceuticals in the United States, it is becoming increasingly evident that Congressional members are under pressure to make the approval process easier. Part One of this series looks at the gaps in the worldwide distribution systems of pharmaceuticals. Part Two examines the breakdown in oversight of the manufacturing process by the federal government. Part Three gives a glaring example of how state governments are dropping the ball. Now, we expand the scope even further. While Michael Moore's...